In Vivo CAR-T Autoimmune Therapy: Reprogramming the Immune System In Situ Introduction CAR-T therapy has already transformed hematologic oncology. Yet its expansion into autoimmune disease has been limited by cost, manufacturing complexity, and scalability challenges. A new paradigm is emerging: in vivo CAR-T autoimmune therapy . Instead of extracting T cells, engineering them ex vivo, and reinfusing them weeks later, in vivo approaches program immune cells directly inside th

Introduction Messenger RNA (mRNA) has redefined what is possible in modern medicine. As a therapeutic platform, it enables rapid vaccine development, personalized cancer immunotherapy, and protein replacement strategies for rare diseases. However, behind every successful mRNA therapeutic lies a carefully engineered synthesis process. While clinical outcomes often dominate the conversation around mRNA therapeutics, the quality of mRNA synthesis ultimately determines translatio